Most people first heard about mRNA vaccines in December 2020, but the idea behind them is older than the pandemic, and the way they work is simpler than the reputation suggests. In short: an mRNA vaccine gives your cells a temporary set of instructions for building one harmless piece of a germ, your immune system practices on it, and the instructions are broken down within days. Here is the process, one step at a time, and what the evidence says about the questions people ask most.

What is mRNA in the first place?

Messenger RNA is a single-stranded copy of a gene. Inside every cell, a gene in DNA is copied into mRNA, and the cell’s protein factories, the ribosomes, read the mRNA three letters at a time and string together amino acids to build a protein. DNA is the long-term archive. mRNA is the working photocopy, and it is deliberately short-lived. In mammalian cells it lasts from minutes to days, which lets a cell change what it makes quickly.

An mRNA vaccine borrows that everyday system. The mRNA in the vial is made in a laboratory rather than copied from a person’s genes, but it is read by the same ribosomes in the same way.

Step one: what instructions does the vaccine carry?

The mRNA is made in a laboratory by copying a DNA template, which is a long-standing technique rather than anything exotic. The mRNA encodes an antigen, a protein from the germ the vaccine is meant to protect against. For the COVID-19 vaccines from Pfizer-BioNTech and Moderna, the antigen is the spike protein found on the surface of the coronavirus. The vaccine contains the code for spike, not the virus. There is no live or weakened virus in it, which is a point the US Centers for Disease Control and Prevention makes directly.

Step two: how does the mRNA get into cells?

It does not get in by itself. mRNA is large, carries a negative charge and is quickly broken down by enzymes that float around in the body. Bare mRNA would mostly be destroyed before reaching anything useful.

The solution is to wrap it in lipid nanoparticles, tiny bubbles of fat-like molecules that protect the mRNA and help it slip into cells. The first lipid nanoparticle drug approved by the US Food and Drug Administration was Onpattro in 2018, a treatment that uses a different kind of RNA. In practice, making these particles was hard to scale. The mixers that blend the mRNA with the lipids were small devices, and Pfizer ran about 100 of them in parallel, while the specialized lipids had to be scaled from grams or kilograms to several tons. New lipids then had to be developed for the longer mRNA strands, and making them at industrial scale was one of the real engineering hurdles of 2020.

Step three: what happens after the shot, and where does the mRNA go?

Injection is into the muscle of the upper arm or thigh. Cells there, along with immune cells called dendritic cells, take up the particles. Inside the cell, ribosomes read the mRNA and build copies of the spike protein. Fragments of that protein are shown on the cell surface, where the immune system can see them.

To the body this looks like a cell that has been infected, minus the infection. Dendritic cells that have picked up the antigen travel to lymph nodes and present it to T cells and B cells. B cells produce antibodies. Some T cells help coordinate the response and others learn to destroy infected cells. Memory cells remain afterward, so a later encounter with the real virus meets a prepared defense.

Cells break it down. According to the CDC, the cell degrades the mRNA after it has made the protein fragment and disposes of it as waste. Reviews put the timeframe at a few days. Nothing about the design is meant to be permanent.

That short life is partly why a booster can be needed. It is also why the sore arm and low-grade fever some people get usually fade within a day or two. Those are signs the immune system is responding, not signs of the mRNA lingering.

Does an mRNA vaccine change your DNA?

This is probably the most common worry, so it deserves a direct answer. No, and the reasons are mechanical rather than reassuring talk. The mRNA stays in the cytoplasm and does not enter the nucleus, where DNA is kept. The CDC states the vaccines do not enter the nucleus and do not affect or interact with a person’s DNA. To write RNA into DNA, a cell needs an enzyme called reverse transcriptase and a route into the nucleus. Retroviruses such as HIV bring both. The vaccine brings neither.

So the idea that the shot rewrites your genes runs against how the molecules behave. The mRNA is read, used and discarded.

Why did it take decades to get here?

The field has a long paper trail. In 1989, researchers first got liposome-packaged mRNA into cells. In 1993, liposome-wrapped viral mRNA stimulated T cells in mice, and in 1994, self-amplifying mRNA was developed. A 1995 study showed mRNA for a tumor antigen could provoke an anti-cancer response in mice. The first human trial, in 2001, used a patient’s own dendritic cells loaded with mRNA. BioNTech was founded in 2008 and Moderna in 2010, and in 2013 the US defense research agency DARPA granted Moderna up to $25 million.

Early versions of mRNA caused trouble. Lab-made mRNA triggers inflammation because immune cells treat it as foreign, and the cells also made little protein from it. Researchers had shown that mRNA could work in animals as early as 1990, when naked mRNA was injected into mouse muscle, but turning that into a medicine proved hard.

The breakthrough came from Katalin Karikó and Drew Weissman. In work published in 2005, they showed that swapping in modified building blocks, similar to those found in natural mammalian RNA, nearly eliminated the inflammatory reaction. Later studies in 2008 and 2010 showed such modified mRNA also produced much more protein. In 2023, the two shared the Nobel Prize in Physiology or Medicine for these discoveries. The Nobel committee noted that two modified mRNA vaccines against the SARS-CoV-2 surface protein reported about 95 percent protection in trials and were approved in December 2020.

How quickly was it developed, and is that a safety worry?

Reactions in the trials were strong but short-lived, and in general similar in kind to those of conventional vaccines. The pandemic accelerated the paperwork and funding, not the underlying science, which had two decades behind it. The first human trial of an mRNA vaccine for an infectious disease, against rabies, was in 2013. On 2 December 2020 the UK regulator MHRA became the first to approve an mRNA vaccine, and the FDA granted emergency use authorization to Pfizer-BioNTech on 11 December 2020, with Moderna about a week later.

More than 13 billion doses of COVID-19 vaccines of all types had been given worldwide by the time of the Nobel announcement. That large exposure is what allowed rare side effects to be spotted. In June 2021, the FDA added a warning about myocarditis and pericarditis, inflammation of the heart or its lining, for some recipients. The CDC describes the common reactions as pain or swelling at the injection site, headache, chills or fever, and calls serious events rare. This is educational information, not medical advice. Questions about a specific person’s situation belong with a doctor or pharmacist.

Storage is a separate matter. The molecule is fragile. Pfizer-BioNTech’s original vaccine was stored between roughly minus 80 and minus 60 degrees Celsius. Moderna’s was kept at minus 25 to minus 15 degrees, about like a home freezer, and stayed stable in an ordinary refrigerator for up to 30 days. Storage requirements have been a key logistics problem, and improving them is an active area of formulation research.

What else could mRNA be used for?

Researchers are working on mRNA vaccines and treatments for influenza, rabies, Zika, cytomegalovirus, chikungunya and certain cancers. A self-amplifying version, which carries instructions for copying itself so that smaller doses might suffice, was authorized in India in June 2022 for COVID-19. In February 2026, according to one reference source, the European Medicines Agency approved a combined COVID-19 and influenza mRNA vaccine for people 50 and older.

A second self-amplifying COVID-19 vaccine, ARCT-154, was authorized in Japan in November 2023. These variants matter because they hint at lower doses and different storage needs, but they are newer and have a shorter track record than the original design.

Cancer is the area where hope runs furthest ahead of results. Trials of mRNA-based approaches have been running since 2001 with dendritic cells and since 2008 with direct injection, but a proven, widely used cancer vaccine of this kind is not yet established.

Common questions

Do mRNA vaccines contain the virus?

No. They contain mRNA coding for one viral protein, plus the lipid nanoparticles and a few other ingredients. They cannot cause the infection they protect against.

How long does the mRNA stay in the body?

A few days. Cells break it down and clear it after use. Mammalian mRNA in general lasts only minutes to days.

Can the vaccine alter my genes?

No. It does not enter the nucleus, and it lacks the machinery that would be needed to insert RNA into DNA.

Why do I feel sick after the shot?

The symptoms, such as fever, fatigue and a sore arm, come from the immune response to the vaccine’s spike instructions and the lipid particles. They usually pass within a day or two. If symptoms are severe or unusual, contact a health professional.

Who won the Nobel Prize for mRNA vaccines?

Katalin Karikó and Drew Weissman, in 2023, for their work on nucleoside base modifications.

What to remember

An mRNA vaccine is a delivery system for a temporary instruction. Lipid nanoparticles carry the mRNA into cells, ribosomes use it to make a harmless piece of a germ, the immune system learns from it, and the mRNA is cleared within days. It does not enter the nucleus and does not change DNA.

The technology rests on decades of work, with the key insight, modified building blocks, published in 2005 and honored with the 2023 Nobel Prize. Its record is large, its side effects are known and monitored, and its uses beyond COVID-19 are still being tested.

Sources